Vaginal drug delivery systems for HIV prevention

AAPS Journal

Volumn 11, Issue 1, 2009, Pages 78-87

  Rohan, Lisa Cencia ^a,b   Sassi, Alexandra B ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Drug delivery; HIV prevention; Microbicides; STI prevention; Vaginal drug delivery

Indexed keywords

ANTIVIRUS AGENT; CARBOMER; CELLULOSE SULFATE; CITRIC ACID; DAPIVIRINE; EDETATE DISODIUM; GLYCEROL; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HYDROXYETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; INTEGRASE INHIBITOR; LACTIC ACID; MACROGOL; METHYL PARABEN; METHYLCELLULOSE; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NANOPARTICLE; PLACEBO; POLYGLACTIN; POLYSTYRENESULFONIC ACID; POLYVINYL ALCOHOL; PRO 2000; PROPYL PARABEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SORBITOL; TENOFOVIR; TERAMEPROCOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FILM; GEL; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEL; INFECTION PREVENTION; NONHUMAN; OINTMENT; REVIEW; SUPPOSITORY; TABLET; UNSPECIFIED SIDE EFFECT; VAGINA RING;

ADMINISTRATION, INTRAVAGINAL; ANTI-HIV AGENTS; BODY FLUIDS; CONTRACEPTIVE DEVICES, FEMALE; DRUG DELIVERY SYSTEMS; FEMALE; HIV INFECTIONS; HUMANS; HYDROGELS; NANOPARTICLES; OINTMENTS; TABLETS; VAGINA;

EID: 65549159648     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9082-7     Document Type: Review

References (135)

1. AIDS epidemic update. In UNAIDS (ed) (UNAIDS, ed), WHO Library Cataloguing-in-Publication Data, (2007).
2. S. Krishnan, M. S. Dunbar, A. M. Minnis, C. A. Medlin, C. E. Gerdts, and N. S. Padian. Poverty, gender inequities, and women's risk of human immunodeficiency virus/AIDS. Ann. N. Y. Acad. Sci. 1136:101-110 (2008).
3. Will there be an HIV vaccine in the next 10 years? Nat. Med. 13:518-519 (2007).
4. R. Pauwels, and E. De Clercq. Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 11:211-221 (1996).
5. J. Balzarini, and L. Van Damme. Microbicide drug candidates to prevent HIV infection. Lancet. 369:787-797 (2007).
6. J. A. Turpin. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert. Opin. Investig. Drugs. 11:1077-1097 (2002).
7. I. Sjoberg. The vagina. Morphological, functional and ecological aspects. Acta. Obstet. Gynecol. Scand. 71:84-85 (1992).
8. J. G. Forsberg. A morphologist's approach to the vagina. Acta. Obstet. Gynecol. Scand. Suppl. 163:3-10 (1996).
9. N. J. Alexander, E. Baker, M. Kaptein, U. Karck, L. Miller, and E. Zampaglione. Why consider vaginal drug administration. Fertil. Steril. 82:1-12 (2004).
10. D. C. Walker, B. H. Brown, A. D. Blackett, J. Tidy, and R. H. Smallwood. A study of the morphological parameters of cervical squamous epithelium. Physiol. Meas. 24:121-135 (2003).
11. A. B. Sassi, C. E. Isaacs, B. J. Moncla, P. Gupta, S. Hillier, and L. C. Rohan. Effects of physiological fluids on physical-chemical characteristics and activity of topical vaginal microbicide products. J. Pharm. Sci. 97:3123-3139 (2007).
12. M. J. Godley. Quantitation of vaginal discharge in healthy volunteers. Br. J. Obstet. Gynaecol. 92:739-742 (1985).
13. C. Treves, M. T. Vincenzini, P. Vanni, F. Bardazzi, A. Cattaneo, and E. Ogier. Changes in enzyme levels in human cervical mucus during the menstrual cycle. Int. J. Fertil. 31:59-66 (1986).
14. E. V. Valore, C. H. Park, S. L. Igreti, and T. Ganz. Antimicrobial components of vaginal fluid. Am. J. Obstet. Gynecol. 187:561-568 (2002).
15. W. B. Rencher. Vaginal Microbicide Formulations Workshop, Lippincott-Raven, Arlington, VA, 2001.
16. B. T. Burruano, R. L. Schnaare, and D. Malamud. Synthetic cervical mucus formulation. Contraception. 66:137-140 (2002).
17. D. F. Katz. Human cervical mucus: Research update. Am. J. Obstet. Gynecol. 165:1984-1986 (1991).
18. P. M. Zavos, and M. R. Cohen. The pH of cervical mucus and the postcoital test. Fertil. Steril. 34:234-238 (1980).
19. L. Ming, P. Xiaoling, L. Yan, W. Lili, W. Qi, Y. Xiyong, W. Boyao, and H. Ning. Purification of antimicrobial factors from human cervical mucus. Hum. Reprod. 22:1810-1815 (2007).
20. F. Acarturk, Z. I. Parlatan, and O. F. Saracoglu. Comparison of vaginal aminopeptidase enzymatic activities in various animals and in humans. J. Pharm. Pharmacol. 53:1499-1504 (2001).
21. J. L. Richardson, and L. Illum. Routes of delivery: Case studies. The vaginal route of peptide and protein drug delivery. Adv. Drug. Deliv. Rev. 8:341-366 (1992).
22. G. F. Schumacher. Biochemistry of cervical mucus. Fertil. Steril. 21:697-705 (1970).
23. G. F. Schumacher, M. H. Kim, A. H. Hosseinian, and C. Dupon. Immunoglobulins, proteinase inhibitors, albumin, and lysozyme in human cervical mucus. I. Communication: Hormonal profiles and cervical mucus changes-methods and results. Am. J. Obstet. Gynecol. 129:629-636 (1977).
24. L. J. Tang, F. De Seta, F. Odreman, P. Venge, C. Piva, S. Guaschino, and R. C. Garcia. Proteomic analysis of human cervical-vaginal fluids. J. Proteome. Res. 6:2874-2883 (2007).
25. S. Dasari, L. Pereira, A. P. Reddy, J. E. Michaels, X. Lu, T. Jacob, A. Thomas, M. Rodland, C. T. Roberts Jr., M. G. Gravett, and S. R. Nagalla. Comprehensive proteomic analysis of human cervical-vaginal fluid. J. Proteome. Res. 6:1258-1268 (2007).
26. J. L. Shaw, C. R. Smith, and E. P. Diamandis. Proteomic analysis of human cervico-vaginal fluid. J. Proteome. Res. 6:2859-2865 (2007).
27. L. L. Klein, K. R. Jonscher, M. J. Heerwagen, R. S. Gibbs, and J. L. McManaman. Shotgun proteomic analysis of vaginal fluid from women in late pregnancy. Reprod. Sci. 15:263-273 (2008).
28. M. K. Di Quinzio, K. Oliva, S. J. Holdsworth, M. Ayhan, S. P. Walker, G. E. Rice, H. M. Georgiou, and M. Permezel. Proteomic analysis and characterisation of human cervico-vaginal fluid proteins. Aust. N. Z. J. Obstet. Gynaecol. 47:9-15 (2007).
29. E. L. Johansson, A. Rudin, L. Wassen, and J. Holmgren. Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunology. 96:272-277 (1999).
30. C. S. Dezzutti, P. C. Guenthner, J. E. Cummins Jr., T. Cabrera, J. H. Marshall, A. Dillberger, and R. B. Lal. Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J. Infect. Dis. 183:1204-1213 (2001).
31. K. B. Collins, B. K. Patterson, G. J. Naus, D. V. Landers, and P. Gupta. Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat. Med. 6:475-479 (2000).
32. M. S. Cohen, J. R. Black, R. A. Proctor, and P. F. Sparling. Host defences and the vaginal mucosa. A re-evaluation. Scand. J. Urol. Nephrol. Suppl. 86:13-22 (1984).
33. B. K. Patterson, A. Landay, J. Andersson, C. Brown, H. Behbahani, D. Jiyamapa, Z. Burki, D. Stanislawski, M. A. Czerniewski, and P. Garcia. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am. J. Pathol. 153:481-490 (1998).
34. J. Pudney, A. J. Quayle, and D. J. Anderson. Immunological microenvironments in the human vagina and cervix: Mediators of cellular immunity are concentrated in the cervical transformation zone. Biol. Reprod. 73:1253-1263 (2005).
35. M. Johansson, and N. Y. Lycke. Immunology of the human genital tract. Curr. Opin. Infect. Dis. 16:43-49 (2003).
36. C. J. Miller, M. McChesney, and P. F. Moore. Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques. Lab. Invest. 67:628-634 (1992).
37. T. Kawamura, S. E. Kurtz, A. Blauvelt, and S. Shimada. The role of Langerhans cells in the sexual transmission of HIV. J. Dermatol. Sci. 40:147-155 (2005).
38. L. de Witte, A. Nabatov, M. Pion, D. Fluitsma, M. A. de Jong, T. de Gruijl, V. Piguet, Y. van Kooyk, and T. B. Geijtenbeek. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat. Med. 13:367-371 (2007).
39. D. Medaglini, C. M. Rush, P. Sestini, and G. Pozzi. Commensal bacteria as vectors for mucosal vaccines against sexually transmitted diseases: vaginal colonization with recombinant streptococci induces local and systemic antibodies in mice. Vaccine. 15:1330-1337 (1997).
40. X. Liu, L. A. Lagenaur, D. A. Simpson, K. P. Essenmacher, C. L. Frazier-Parker, Y. Liu, D. Tsai, S. S. Rao, D. H. Hamer, T. P. Parks, P. P. Lee, and Q. Xu. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob. Agents. Chemother. 50:3250-3259 (2006).
41. N. F. Ho, L. Suhardja, S. Hwang, E. Owada, A. Molokhia, G. L. Flynn, W. I. Higuchi, and J. Y. Park. Systems approach to vaginal delivery of drugs III: Simulation studies interfacing steroid release from silicone matrix and vaginal absorption in rabbits. J. Pharm. Sci. 65:1578-1585 (1976).
42. S. Hwang, E. Owada, T. Yotsuyanagi, L. Suhardja, N. F. Ho, G. L. Flynn, and W. I. Higuchi. Systems approach to vaginal delivery of drugs II: In situ vaginal absorption of unbranched aliphatic alcohols. J. Pharm. Sci. 65:1574-1578 (1976).
43. S. Hwang, E. Owada, L. Suhardja, N. F. Ho, G. L. Flynn, and W. I. Higuchi. Systems approach to vaginal delivery of drugs IV: Methodology for determination of membrane surface pH. J. Pharm. Sci. 66:778-781 (1977).
44. S. Hwang, E. Owada, L. Suhardja, N. F. Ho, G. L. Flynn, and W. I. Higuchi. Systems approach to vaginal delivery of drugs V: In situ vaginal absorption of 1-alkanoic acids. J. Pharm. Sci. 66:781-784 (1977).
45. T. Yotsuyanagi, A. Molokhia, S. Hwang, N. F. Ho, G. L. Flynn, and W. I. Higuchi. Systems approach to vaginal delivery of drugs I: Development of in situ vaginal drug absorption procedure. J. Pharm. Sci. 64:71-76 (1975).
46. A. D. Woolfson, R. K. Malclm, and R. Gallagher. Drug delivery by the intravaginal route. Crit. Rev. Ther. Drug. Carrier. Syst. 17:509-555 (2000).
47. H. Okada, and A. M. Hillery. Vaginal Drug Delivery, Taylor & Francis, New York, 2001.
48. V. H. Lee. Enzymatic barriers to peptide and protein absorption. Crit. Rev. Ther. Drug Carr. Syst. 5:69-97 (1988).
49. Y. van Herrewege, J. Michiels, J. van Roey, K. Fransen, L. Kestens, J. Balzarini, P. Lewi, G. Vanham, and P. Janssen. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob. Agents Chemother. 48:337-339 (2004).
50. L. C. Rohan, D. Ratner, K. McCullough, S. L. Hiller, and P. Gupta. Measurement of anti-HIV activity of marketed vaginal products and excipients using a PBMC-based in vitro assay. Sex. Transm. Dis. 31:143-148 (2004).
51. C. K. Mauck, D. H. Weiner, M. D. Creinen, K. T. Barnhart, M. M. Callahan, and R. Bax. A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II. Contraception. 70:233-240 (2004).
52. M. M. Lederman, R. S. Veazey, R. Offord, D. E. Mosier, J. Dufour, M. Mefford, M. Piatak Jr., J. D. Lifson, J. R. Salkowitz, B. Rodriguez, A. Blauvelt, and O. Hartley. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science. 306:485-487 (2004).
53. O. J. D'Cruz, P. Samuel, and F. M. Uckun. PHI-443: A novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide. Biol. Reprod. 71:2037-2047 (2004).
54. K. H. Mayer, S. A. Karim, C. Kelly, L. Maslankowski, H. Rees, A. T. Profy, J. Day, J. Welch, and Z. Rosenberg. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. Aids. 17:321-329 (2003).
55. P. F. Harrison, Z. Rosenberg, and J. Bowcut. Topical microbicides for disease prevention: Status and challenges. Clin. Infect. Dis. 36:1290-1294 (2003).
56. S. Garg, K. Vermani, G. Kohli, R. Kandarapu, K. R. Tambwekar, A. Garg, D. P. Waller, and L. J. Zaneveld. Survey of vaginal formulations available on the Indian market: Physicochemical characterization of selected products. Int. J. Pharmaceut. Med. 16:141-152 (2002).
57. K. Vermani, and S. Garg. The scope and potential of vaginal drug delivery. Pharm. Sci. Technol. Today. 3:359-364 (2000).
58. C. Coggins, K. Blanchard, F. Alvarez, V. Brache, E. Weisberg, P. H. Kilmarx, M. Lacarra, R. Massai, D. Mishell Jr., A. Salvatierra, P. Witwatwongwana, C. Elias, and C. Ellertson. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex. Transm. Infect. 76:480-483 (2000).
59. S. Joshi, N. Joglekar, M. Ghate, J. Unni, A. Risbud, M. Bentley, M. Shepherd, R. Bollinger, and S. Mehendale. Phase I safety & preliminary acceptability of nonoxynol-9 vaginal pessary as a vaginal microbicide in low risk women in Pune, India. Indian J. Med. Res. 117:152-157 (2003).
60. L. van Damme, A. Wright, K. Depraetere, I. Rosenstein, V. Vandersmissen, L. Poulter, M. McKinlay, E. Van Dyck, J. Weber, A. Profy, M. Laga, and V. Kitchen. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex. Transm. Infect. 76:126-130 (2000).
61. E. Hardy, A. L. Jimenez, K. S. de Padua, and L. J. Zaneveld. Women's preferences for vaginal antimicrobial contraceptives. III. Choice of a formulation, applicator, and packaging. Contraception. 58:245-249 (1998).
62. J. Romano, R. K. Malcolm, S. Garg, L. Rohan, and P. Kaptur. Microbicide delivery: Formulation technologies and strategies. Current. Opinion. in. HIV. & AIDS. 3:558-566 (2008).
63. S. Garg, K. R. Tambwekar, K. Vermani, R. Kandarapu, A. Garg, D. P. Waller, and L. J. Zaneveld. Development pharmaceutics of microbicide formulations. Part II: Formulation, evaluation, and challenges. AIDS. Patient. Care. STDS. 17:377-399 (2003).
64. H. Thormar, G. Bergsson, E. Gunnarsson, G. Georgsson, M. Witvrouw, O. Steingrimsson, E. De Clercq, and T. Kristmundsdottir. Hydrogels containing monocaprin have potent microbicidal activities against sexually transmitted viruses and bacteria in vitro. Sex. Transm. Infect. 75:181-185 (1999).
65. J. das Neves, and M. F. Bahia. Gels as vaginal drug delivery systems. Int. J. Pharm. 318:1-14 (2006).
66. J. R. Hwu, W. N. Tseng, J. Gnabre, P. Giza, and R. C. Huang. Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation. J. Med. Chem. 41:2994-3000 (1998).
67. H. Chen, L. Teng, J. N. Li, R. Park, D. E. Mold, J. Gnabre, J. R. Hwu, W. N. Tseng, and R. C. Huang. Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. J. Med. Chem. 41:3001-3007 (1998).
68. N. Khanna, R. Dalby, A. Connor, A. Church, J. Stern, and N. Frazer. Phase I clinical trial of repeat dose terameprocol vaginal ointment in healthy female volunteers. Sex. Transm. Dis. 35:577-582 (2008).
69. N. Khanna, R. Dalby, M. Tan, S. Arnold, J. Stern, and N. Frazer. Phase I/ II clinical safety studies of terameprocol vaginal ointment. Gynecol. Oncol. 107:554-562 (2007).
70. J. E. Darroch, and J. J. Frost. Women's interest in vaginal microbicides. Fam. Plann. Perspect. 31:16-23 (1999).
71. B. Y. Holt, V. G. Morwitz, L. Ngo, P. F. Harrison, K. J. Whaley, A. Pettifor, and A. H. Nguyen. Microbicide preference among young women in California. J. Womens. Health. (Larchmt). 15:281-294 (2006).
72. S. Braunstein, and J. van de Wijgert. Preferences and practices related to vaginal lubrication: Implications for microbicide acceptability and clinical testing. J. Womens Health (Larchmt). 14:424-233 (2005).
73. J. A. Cohen, M. S. Steele, F. I. Urena, and M. E. Beksinska. Microbicide applicators: Understanding design preferences among women in the dominican republic and South Africa. Sex. Transm. Dis. 34:15-19 (2007).
74. M. Rader, G. Marks, G. Mansergh, N. Crepaz, L. C. Miller, P. R. Appleby, and S. Murphy. Preferences about the characteristics of future HIV prevention products among men who have sex with men. AIDS Educ. Prev. 13:149-159 (2001).
75. B. A. Auslander, M. M. Perfect, D. M. Breitkopf, P. A. Succop, and S. L. Rosenthal. Microbicides: Information, beliefs, and preferences for insertion. J. Womens Health (Larchmt). 16:1458-1467 (2007).
76. S. Garg, R. A. Anderson, C. J. Chany 2nd, D. P. Waller, X. H. Diao, K. Vermani, and L. J. Zaneveld. Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). Contraception. 64:67-75 (2001).
77. D. Tien, R. L. Schnaare, F. Kang, G. Cohl, T. J. McCormick, T. R. Moench, G. Doncel, K. Watson, R. W. Buckheit, M. G. Lewis, J. Schwartz, K. Douville, and J. W. Romano. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res. Hum. Retroviruses. 21:845-853 (2005).
78. F. M. Behets, A. N. Turner, K. Van Damme, N. L. Rabenja, N. Ravelomanana, T. A. Swezey, A. J. Bell, D. R. Newman, D. L. Williams, and D. J. Jamieson. Vaginal Microbicide and Diaphragm Use for Sexually Transmitted Infection Prevention: A Randomized Acceptability and Feasibility Study Among High-Risk Women in Madagascar. Sex. Transm. Dis. 35:818-826 (2008).
79. K. H. Mayer, J. Peipert, T. Fleming, A. Fullem, T. Moench, S. Cu-Uvin, M. Bentley, M. Chesney, and Z. Rosenberg. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin. Infect. Dis. 32:476-482 (2001).
80. S. A. Ballagh, V. Brache, C. Mauck, M. M. Callahan, L. Cochon, A. Wheeless, and T. R. Moench. A Phase I study of the functional performance, safety and acceptability of the BufferGel Duet. Contraception. 77:130-137 (2008).
81. R. A. Maguire, V. R. Zacharopoulos, and D. M. Phillips. Carrageenan-based nonoxynol-9 spermicides for prevention of sexually transmitted infections. Sex. Transm. Dis. 25:494-500 (1998).
82. R. Pearce-Pratt, and D. M. Phillips. Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol. Reprod. 54:173-182 (1996).
83. J. E. Cummins Jr., J. Guarner, L. Flowers, P. C. Guenthner, J. Bartlett, T. Morken, L. A. Grohskopf, L. Paxton, and C. S. Dezzutti. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob. Agents. Chemother. 51:1770-1779 (2007).
84. J. H. van de Wijgert, S. L. Braunstein, N. S. Morar, H. E. Jones, L. Madurai, T. T. Strickfaden, M. Moodley, J. Aboobaker, G. Ndlovu, T. M. Ferguson, B. A. Friedland, C. E. Hart, and G. Ramjee. Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa. J. Acquir. Immune. Defic. Syndr. 46:538-546 (2007).
85. P. H. Kilmarx, K. Blanchard, S. Chaikummao, B. A. Friedland, N. Srivirojana, C. Connolly, P. Witwatwongwana, S. Supawitkul, P. A. Mock, T. Chaowanachan, and J. Tappero. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand. Sex. Transm. Dis. 35:226-232 (2008).
86. R. A. Anderson, K. A. Feathergill, X. H. Diao, M. D. Cooper, R. Kirkpatrick, B. C. Herold, G. F. Doncel, C. J. Chany, D. P. Waller, W. F. Rencher, and L. J. Zaneveld. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J. Androl. 23:426-438 (2002).
87. R. A. Anderson, K. Feathergill, X. H. Diao, C. Chany 2nd, W. F. Rencher, L. J. Zaneveld, and D. P. Waller. Contraception by Ushercell (cellulose sulfate) in formulation: Duration of effect and dose effectiveness. Contraception. 70:415-422 (2004).
88. W. M. El-Sadr, K. H. Mayer, L. Maslankowski, C. Hoesley, J. Justman, F. Gai, C. Mauck, J. Absalon, K. Morrow, B. Masse, L. Soto-Torres, and A. Kwiecien. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. Aids. 20:1109-1116 (2006).
89. L. van Damme, R. Govinden, F. M. Mirembe, F. Guedou, S. Solomon, M. L. Becker, B. S. Pradeep, A. K. Krishnan, M. Alary, B. Pande, G. Ramjee, J. Deese, T. Crucitti, and D. Taylor. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359:463-472 (2008).
90. W. Tao, C. Richards, and D. Hamer. Enhancement of HIV infection by cellulose sulfate. AIDS. Res. Hum. Retroviruses. 24:925-929 (2008).
91. N. Bolognesi. AIDS gel's failure calls prevention approach into question. Nat. Med. 13:230 (2007).
92. V. A. Jespers, J. M. Van Roey, G. I. Beets, and A. M. Buve. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J. Acquir. Immune. Defic. Syndr. 44:154-158 (2007).
93. N. Bourne, D. I. Bernstein, J. Ireland, A. J. Sonderfan, A. T. Profy, and L. R. Stanberry. The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. J. Infect. Dis. 180:203-205 (1999).
94. L. Van Damme, A. Wright, K. Depraetere, I. Rosenstein, V. Vandersmissen, L. Poulter, M. McKinlay, E. Van Dyck, J. Weber, A. Profy, M. Laga, and V. Kitchen. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex. Transm. Infect. 76:126-130 (2000).
95. P. S. Fletcher, and R. J. Shattock. PRO-2000, an antimicrobial gel for the potential prevention of HIV infection. Curr Opin Investig Drugs. 9:189-200 (2008).
96. K. H. Mayer, L. A. Maslankowski, F. Gai, W. M. El-Sadr, J. Justman, A. Kwiecien, B. Masse, S. H. Eshleman, C. Hendrix, K. Morrow, J. F. Rooney, and L. Soto-Torres. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. Aids. 20:543-551 (2006).
97. R. K. Rosen, K. M. Morrow, A. Carballo-Dieguez, J. E. Mantell, S. Hoffman, F. Gai, L. Maslankowski, W. M. El-Sadr, and K. H. Mayer. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: A mixed-methods study. J. Womens. Health. (Larchmt). 17:383-392 (2008).
98. D. L. Patton, Y. T. Cosgrove Sweeney, J. E. Balkus, L. C. Rohan, B. J. Moncla, M. A. Parniak, and S. L. Hillier. Preclinical Safety Assessments of UC781 Anti-HIV Topical Microbicide Formulations. Antimicrob. Agents. Chemother. 51:1608-1615 (2007).
99. J. L. Schwartz, G. Kovalevsky, J. J. Lai, S. A. Ballagh, T. McCormick, K. Douville, C. K. Mauck, and M. M. Callahan. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. Sex. Transm. Dis. 35:414-419 (2008).
100. I. M. Malonza, F. Mirembe, C. Nakabiito, L. O. Odusoga, O. A. Osinupebi, K. Hazari, S. Chitlange, M. M. Ali, M. Callahan, and L. Van Damme. Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. Aids. 19:2157-2163 (2005).
101. J. L. Schwartz, C. Mauck, J. J. Lai, M. D. Creinin, V. Brache, S. A. Ballagh, D. H. Weiner, S. L. Hillier, R. N. Fichorova, and M. Callahan. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception. 74:133-140 (2006).
102. C. Mauck, D. H. Weiner, S. Ballagh, M. Creinin, D. F. Archer, J. Schwartz, H. Pymar, J. J. Lai, and M. Callahan. Single and multiple exposure tolerance study of cellulose sulfate gel: A Phase I safety and colposcopy study. Contraception. 64:383-391 (2001).
103. M. E. Bentley, A. M. Fullem, E. E. Tolley, C. W. Kelly, N. Jogelkar, N. Srirak, L. Mwafulirwa, G. Khumalo-Sakutukwa, and D. D. Celentano. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am. J. Public. Health. 94:1159-1164 (2004).
104. K. Morrow, R. Rosen, L. Richter, A. Emans, A. Forbes, J. Day, N. Morar, L. Maslankowski, A. T. Profy, C. Kelly, S. S. Abdool Karim, and K. H. Mayer. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J. Womens. Health. (Larchmt). 12:655-666 (2003).
105. S. A. Ballagh, J. M. Baker, D. M. Henry, and D. F. Archer. Safety of single daily use for one week of C31G HEC gel in women. Contraception. 66:369-375 (2002).
106. C. K. Mauck, D. H. Weiner, S. A. Ballagh, M. D. Creinin, D. F. Archer, J. L. Schwartz, H. C. Pymar, J. J. Lai, W. F. Rencher, and M. M. Callahan. Single and multiple exposure tolerance study of polystyrene sulfonate gel: A phase I safety and colposcopy study. Contraception. 70:77-83 (2004).
107. N. Coetzee, K. Blanchard, C. Ellertson, A. A. Hoosen, and B. Friedland. Acceptability and feasibility of Micralax applicators and of methyl cellulose gel placebo for large-scale clinical trials of vaginal microbicides. Aids. 15:1837-1842 (2001).
108. M. E. Bentley, K. M. Morrow, A. Fullem, M. A. Chesney, S. D. Horton, Z. Rosenberg, and K. H. Mayer. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam. Plann. Perspect. 32:184-148 (2000).
109. A. D. Woolfson, R. K. Malcolm, R. J. Morrow, C. F. Toner, and S. D. McCullagh. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int. J. Pharm. 325:82-89 (2006).
110. K. M. Gupta, S. M. Pearce, A. E. Poursaid, H. A. Aliyar, P. A. Tresco, M. A. Mitchnik, and P. F. Kiser. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J. Pharm. Sci. 97(10):4228-4239 (2008).
111. C. Elias, and C. Coggins. Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going. J. Womens. Health. Gend. Based. Med. 10:163-173 (2001).
112. A. Dinge, and M. Nagarsenker. Formulation and evaluation of fast dissolving films for delivery of triclosan to the oral cavity. AAPS. PharmSciTech. 9:349-356 (2008).
113. S. Singh, S. Jain, M. S. Muthu, S. Tiwari, and R. Tilak. Preparation and evaluation of buccal bioadhesive films containing clotrimazole. AAPS. PharmSciTech. 9:660-667 (2008).
114. B. Vondrak, and S. Barnhart. Dissolvable films: Dissolvable films for flexible product format in drug delivery. Pharm. Tech. (2008).
115. M. H. Pan, Y. C. Liang, S. Y. Lin-Shiau, N. Q. Zhu, C. T. Ho, and J. K. Lin. Induction of apoptosis by the oolong tea polyphenol theasinensin A through cytochrome c release and activation of caspase-9 and caspase-3 in human U937 cells. J. Agric. Food Chem. 48:6337-6346 (2000).
116. S. Garg, K. Vermani, A. Garg, R. A. Anderson, W. B. Rencher, and L. J. Zaneveld. Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent. Pharm. Res. 22:584-595 (2005).
117. C. K. Mauck, J. M. Baker, S. P. Barr, T. J. Abercrombie, and D. F. Archer. A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9. Postcoital testing and colposcopy. Contraception. 56:89-96 (1997).
118. R. E. Roddy, L. Zekeng, K. A. Ryan, U. Tamoufe, S. S. Weir, and E. L. Wong. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N. Engl. J. Med. 339:504-510 (1998).
119. H. Lu, Q. Zhao, G. Wallace, S. Liu, Y. He, R. Shattock, A. R. Neurath, and B. S. Jiang. Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. AIDS Res. Hum. Retroviruses. 22:411-418 (2006).
120. T. Gyotoku, L. Aurelian, and A. R. Neurath. Cellulose acetate phthalate (CAP): An "inactive" pharmaceutical excipient with antiviral activity in the mouse model of genital herpesvirus infection. Antivir. Chem. Chemother. 10:327-332 (1999).
121. A. R. Neurath, N. Strick, Y. Y. Li, and A. K. Debnath. Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC. Infect. Dis. 1:17 (2001).
122. A. R. Neurath, N. Strick, and Y. Y. Li. Water dispersible microbicidal cellulose acetate phthalate film. BMC. Infect. Dis. 3:27 (2003).
123. P. Raghuvanshi, R. Bagga, D. Malhotra, S. Gopalan, and G. P. Talwar. Spermicidal & contraceptive properties of Praneem polyherbal pessary. Indian. J. Med. Res. 113:135-141 (2001).
124. R. Bagga, P. Raghuvanshi, S. Gopalan, S. K. Das, R. Baweja, S. Suri, D. Malhotra, S. Khare, and G. P. Talwar. A polyherbal vaginal pessary with spermicidal and antimicrobial action: Evaluation of its safety. Trans. R. Soc. Trop. Med. Hyg. 100:1164-1167 (2006).
125. S. Joshi, S. Dutta, B. K. Kumar, U. Katti, S. Kulkarni, A. Risbud, and S. Mehendale. Expanded Safety Study of Praneem Polyherbal vaginal tablet among HIV un-infected women in Pune, India: A Phase II clinical trial report. Sex Transm Infect. 84:343-347 (2008).
126. N. S. Joglekar, S. N. Joshi, S. N. Navlakha, U. R. Katti, and S. M. Mehendale. Acceptability of Praneem polyherbal vaginal tablet among HIV uninfected women & their male partners in Pune, India-Phase I study. Indian. J. Med. Res. 123:547-552 (2006).
127. A. Ham, M. Cost, A. Sassi, C. Dezzutti, and L. Rohan. Targeted Delivery of PSC-RANTES for HIV-1 Prevention using Biodegradable Nanoparticles. Pharm. Res. (2008). In press.
128. S. McCormack, R. Hayes, C. J. Lacey, and A. M. Johnson. Microbicides in HIV prevention. British. Medical. Journal. 322:410-413 (2001).
129. J. A. Turpin, M. L. Schito, L. M. Jenkins, J. K. Inman, and E. Appella. Topical microbicides: A promising approach for controlling the AIDS pandemic via retroviral zinc finger inhibitors. Adv. Pharmacol. 56:229-256 (2008).
130. S. L. Lard-Whiteford, D. Matecka, J. J. O'Rear, I. S. Yuen, C. Litterst, and P. Reichelderfer. Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: An update. J. Acquir. Immune. Defic. Syndr. 36:541-552 (2004).
131. J. G. Clarke, J. F. Peipert, S. L. Hillier, W. Heber, L. Boardman, T. R. Moench, and K. Mayer. Microflora changes with the use of a vaginal microbicide. Sex. Transm. Dis. 29:288-293 (2002).
132. B. J. Moncla, and S. L. Hillier. Why nonoxynol-9 may have failed to prevent acquisition of Neisseria gonorrhoeae in clinical trials. Sex. Transm. Dis. 32:491-494 (2005).
133. B. J. Moncla, K. Pryke, and C. E. Isaacs. Killing of Neisseria gonorrhoeae, Streptococcus agalactiae (group B streptococcus), Haemophilus ducreyi, and vaginal Lactobacillus by 3-O-octyl-sn-glycerol. Antimicrob. Agents. Chemother. 52:1577-1579 (2008).
134. C. A. Schreiber, L. A. Meyn, M. D. Creinin, K. T. Barnhart, and S. L. Hillier. Effects of long-term use of nonoxynol-9 on vaginal flora. Obstet. Gynecol. 107:136-143 (2006).
135. Q1A(R2): Stability Testing of New Drug Substances and Products (Second Revision), ICH Harmonised Tripartite Guideline, 2003.